{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-000785","form_type":"8-K","ticker":"ADPT","cik":"0001478320","company_name":"Adaptive Biotechnologies Corp","filed_at":"2022-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.652184+00:00","generated_at":"2026-06-27T19:21:20.405448+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adaptive Biotechnologies guides FY2021 revenue $153M-$154M (+56% YoY); CFO Cohen to resign","bullets":["FY2021 preliminary revenue $153M-$154M, up ~56% from $98.4M in 2020.","CFO Chad Cohen resigns effective ~Feb 15, 2022 after 10-K filing; no disagreement.","Principal Accounting Officer Kyle Piskel to serve as interim CFO; permanent search initiated.","Preliminary results subject to change; full results expected around Feb 15, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-000785","json":"https://secwatch.observer/filing/0001564590-22-000785.json","markdown":"https://secwatch.observer/filing/0001564590-22-000785.md","text":"https://secwatch.observer/filing/0001564590-22-000785.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1478320/000156459022000785/0001564590-22-000785-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1478320/000156459022000785/adpt-8k_20220104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T19:21:20.405448+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a63da3521c","claim":"Kyle Piskel was appointed as Chief Financial Officer at Adaptive Biotechnologies Corp.","evidence_excerpt":"after which Mr. Kyle Piskel, the Company’s Principal Accounting Officer, will act as Chief Financial Officer and principal financial officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1478320/000156459022000785/0001564590-22-000785-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"de84307571","claim":"Chad Cohen resigned as Chief Financial Officer at Adaptive Biotechnologies Corp.","evidence_excerpt":"On January 4, 2022, Chad Cohen, Chief Financial Officer of the Company, notified the Company of his decision to resign as Chief Financial Officer of the Company, effective following the filing of the Company’s Annual Report on Form 10-K for the period ended December 31, 2021, on or about February 15, 2022, after which Mr. Kyle Piskel, the Company’s Principal Accounting Officer, will act as Chief Financial Officer and principal financial officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1478320/000156459022000785/0001564590-22-000785-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}